Chromocell Therapeutics Corp
AMEX:CHRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Chromocell Therapeutics Corp
AMEX:CHRO
|
US |
|
Senmiao Technology Ltd
NASDAQ:AIHS
|
CN |
|
Alfio Bardolla Training Group SpA
MIL:ABTG
|
IT |
|
T
|
Taekwang Industrial Co Ltd
KRX:003240
|
KR |
|
Repco Home Finance Ltd
NSE:REPCOHOME
|
IN |
|
Faurecia SE
OTC:FURCF
|
FR |
|
Dolby Laboratories Inc
NYSE:DLB
|
US |
|
N
|
Neon Bloom Inc
OTC:NBCO
|
US |
|
Alkaline Water Company Inc
OTC:WTER
|
US |
|
Piedmont Office Realty Trust Inc
NYSE:PDM
|
US |
|
J
|
Janone Inc
F:5AR1
|
US |
|
T
|
Teton Advisors Inc
OTC:TETAA
|
US |
Chromocell Therapeutics Corp
Chromocell Therapeutics Corp is a US-based company operating in Biotechnology industry. The company is headquartered in North Brunswick, New Jersey and currently employs 3 full-time employees. The company went IPO on 2024-02-16. Chromocell Therapeutics Corporation is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. The firm's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.
Chromocell Therapeutics Corp is a US-based company operating in Biotechnology industry. The company is headquartered in North Brunswick, New Jersey and currently employs 3 full-time employees. The company went IPO on 2024-02-16. Chromocell Therapeutics Corporation is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. The firm's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.
